Regenerative Medicine Advanced Therapy Stocks List

Symbol	Grade	Name	% Change
INAB	C	IN8bio, Inc.	-0.21
LCTX	D	Lineage Cell Therapeutics, Inc.	-2.33
HUMA	F	Humacyte, Inc.	-0.10
PROK	F	ProKidney Corp.	-21.16

Related Industries: Biotechnology

Symbol	Grade	Name	Weight
CBSE	B	Changebridge Capital Sustainable Equity ETF	2.56
CBLS	A	Changebridge Capital Long/Short Equity ETF	2.11
FYC	B	First Trust Small Cap Growth AlphaDEX Fund	0.23
XBI	D	SPDR S&P Biotech ETF	0.19
IWC	B	iShares Microcap ETF	0.15

Compare ETFs

Compare CBSE to CBLS Compare CBSE to FYC Compare FYC to IWC

Date	Stock	Title
Nov 14	INAB	INAB: Upcoming Presentations at SNO & ASH
Nov 14	HUMA	Humacyte prices 2.8M shares at $5.34 in registered direct offering
Nov 14	HUMA	Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
Nov 14	LCTX	Earnings Scheduled For November 14, 2024
Nov 13	INAB	IN8bio GAAP EPS of -$0.15
Nov 12	LCTX	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
Nov 12	INAB	IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Nov 12	PROK	ProKidney GAAP EPS of -$0.14
Nov 12	PROK	ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Nov 12	INAB	IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

Regenerative Medicine Advanced Therapy: Regenerative Medicine Advanced Therapy (RMAT) is a designation given by the Food and Drug Administration to drug candidates intended to treat serious or life-threatening conditions under the 21st Century Cures Act. A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints.RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.